Searched over 200M research papers
10 papers analyzed
These studies suggest atorvastatin primarily works by inhibiting HMG-CoA reductase to lower cholesterol, while also affecting various cellular pathways to reduce oxidative stress, inflammation, and apoptosis.
20 papers analyzed
Atorvastatin is a widely used statin, primarily known for its lipid-lowering properties. It is commonly prescribed to manage hypercholesterolemia and prevent cardiovascular diseases. However, its mechanism of action extends beyond cholesterol reduction, involving various cellular and molecular pathways.
Atorvastatin functions by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which plays a crucial role in cholesterol biosynthesis. This inhibition leads to a decrease in cholesterol production in the liver, resulting in upregulation of LDL receptors and increased clearance of low-density lipoprotein (LDL) from the bloodstream .
Atorvastatin has been shown to improve lipid metabolism and mitochondrial function by downregulating miR-21 expression and upregulating peroxisome proliferator-activated receptor-alpha (PPARα). This action helps alleviate lipid metabolism disorders and reduce mitochondrial dynamics and inflammation, particularly in diabetic nephropathy.
Atorvastatin exerts significant anti-inflammatory effects by modulating the expression of various cytokines and proteins. It inhibits the expression of pro-inflammatory adipokines such as interleukin-6 (IL-6) and enhances the expression of anti-inflammatory adipokines like adiponectin. Additionally, atorvastatin induces apoptosis in proliferating and differentiating preadipocytes, which may contribute to its anti-inflammatory properties.
Atorvastatin has been found to reduce oxidative stress in various tissues, including the liver and brain. It decreases the production of reactive oxygen species (ROS) and enhances antioxidant enzyme activities, thereby protecting cells from oxidative damage. This effect is particularly beneficial in conditions like Alzheimer's disease, where oxidative stress plays a significant role in disease progression .
Pyroptosis, a form of programmed cell death, is implicated in atherosclerosis. Atorvastatin inhibits pyroptosis in human vascular endothelial cells by upregulating long non-coding RNA (lncRNA) NEXN-AS1 and NEXN, which in turn downregulates the expression of inflammasome pathway biomarkers such as NLRP3, caspase-1, and IL-1β. This pathway provides a novel mechanism for atorvastatin's protective effects against atherosclerosis.
Atorvastatin improves endothelial function by promoting the degradation of FOXO1 and ICAM-1 through the S-phase kinase-associated protein 2 (Skp2) pathway. This action reduces endothelial dysfunction, which is a common complication in diabetes, thereby enhancing vascular health.
Atorvastatin's mechanism of action is multifaceted, involving the inhibition of HMG-CoA reductase, modulation of lipid metabolism, anti-inflammatory and anti-apoptotic effects, protection against oxidative stress, regulation of pyroptosis, and improvement of endothelial function. These diverse actions contribute to its efficacy in managing hypercholesterolemia and preventing cardiovascular diseases, as well as its potential benefits in other conditions such as diabetic nephropathy and Alzheimer's disease.
Most relevant research papers on this topic